Lindbrook Capital’s AngioDynamics ANGO Stock Holding History

Lindbrook Capital’s Portfolio ANGO Stock Details ANGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-39	Closed	-$285	–	2694
2023 Q3	$285	Sell	39 -530	-93%	-$4.41K	﹤0.01%	2611
2023 Q2	$5.93K	Buy	569 +516	+974%	+$4.97K	﹤0.01%	1721
2023 Q1	$548	Buy	+53	New	+$678	﹤0.01%	2584
2022 Q4	–	Sell	-261	Closed	-$5K	–	2829
2022 Q3	$5K	Buy	+261	New	+$5.73K	﹤0.01%	1632

Other funds holding ANGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Lindbrook Capital's ANGO Position: Q4 2023 in Review

Lindbrook Capital sold out of AngioDynamics (ANGO) in Q4 2023, closing a stake of 39 shares — an estimated $285 sold.

Lindbrook Capital first reported a position in ANGO in Q3 2022 and held it in 4 quarters. The position peaked at $5.93K in Q2 2023. 150 funds tracked by Wall St. Rank hold ANGO as of Q4 2023.

Lindbrook Capital reported no remaining AngioDynamics position as of Q4 2023 after selling out during the quarter.
Lindbrook Capital sold 39 AngioDynamics shares in Q4 2023, an estimated $285.
Lindbrook Capital first reported a position in AngioDynamics in Q3 2022 and held it in 4 quarters.
Lindbrook Capital's AngioDynamics position peaked at $5.93K in Q2 2023.
150 funds tracked by Wall St. Rank held AngioDynamics as of Q4 2023.

Based on Lindbrook Capital's 13F filing for Q4 2023, filed 1 Feb 2024.